论文部分内容阅读
目的:探讨前列地尔辅助治疗早期糖尿病肾病的可行性。方法:选取2012年7月至2014年7月我院收治的早期糖尿病肾病患者78例为研究对象。随机分为实验组与对照组,各39例。对照组患者予以常规饮食控制、适当运动、降糖、调脂等基础性治疗,另给予替米沙坦治疗,实验组患者在对照组患者的基础上加用前列地尔进行辅助治疗。治疗结束后,对两组患者的血肌酐、血尿素氮及24h尿蛋白排泄率(UAER)及不良反应发生情况进行比较。结果:治疗后同组血肌酐、血尿素氮较治疗前无明显差异(p>0.05);同组24h尿蛋白排泄率均较治疗前下降,差异有统计学意义(p<0.05);而实验组下降幅度交对照组更为显著,差异有统计学意义(p<0.05);两组不良反应发生率无显著性差异。(p>0.05)结论:前列地尔辅助替米沙坦治疗早期糖尿病肾病可有效的减少尿蛋白的产生,保护肾功能,疗效满意,且无明显的不良反应,适宜于临床推广应用。
Objective: To investigate the feasibility of alprostadil adjuvant treatment of early diabetic nephropathy. Methods: From July 2012 to July 2014, 78 cases of early diabetic nephropathy admitted to our hospital were selected as the research object. Randomly divided into experimental group and control group, 39 cases each. Patients in the control group were given basic diet control, appropriate exercise, hypoglycemic, lipid-lowering and other basic treatment, the other given telmisartan treatment, patients in the experimental group in the control group based on the use of alprostadil adjuvant therapy. After treatment, serum creatinine, blood urea nitrogen and urinary protein excretion rate (UAER) and adverse reactions were compared between the two groups. Results: The serum creatinine and blood urea nitrogen in the same group had no significant difference (p> 0.05) before treatment, while the excretion rate of 24h urine protein in the same group decreased compared with that before treatment (p <0.05) The decline rate of the group was more significant in the control group, the difference was statistically significant (p <0.05). There was no significant difference in the incidence of adverse reactions between the two groups. (P0.05) .Conclusion: Alprostadil adjuvant telmisartan treatment of early diabetic nephropathy can effectively reduce the production of urinary protein and protect renal function, with satisfactory curative effect and no obvious adverse reactions, which is suitable for clinical application.